trial
as of 2026-07-01Relapse Prevention Study in Patients With Schizophrenia
NCTId NCT01291511
at a glance
Phase 3 · Completed
Enrollment 635 (actual)
Sponsored by Vanda Pharmaceuticals
Primary completion 2014-03
Synthesized from structured facts only — each point cited above.
Design & status
Phase
Phase 3
Status
Completed
Enrollment
635 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Quadruple
Start
2011-02
Primary completion
2014-03
Eligibility
ALL · 18 Years · 65 Years
Interventions & indications
Drugs
Indications
Sponsors
Vanda PharmaceuticalsLead Sponsor
Sites
63 total
Anaheim, United StatesBellflower, United StatesCosta Mesa, United StatesEscondido, United StatesLa Habra, United StatesOceanside, United StatesOrange, United StatesPico Rivera, United StatesRiverside, United StatesSan Diego, United StatesSan Diego, United StatesSan Diego, United States
Linked catalysts
1
Facts & assertions
4 sourced
Enrollment
635
Phase
PHASE3
Primary Completion Date
2014-03
Status
COMPLETED
relationships
The graph out of here
drug
drug
lead_sponsor
company
indication